ArticleKidney medicine
Renal Tubular Acidosis and Immune Checkpoint Inhibitor Therapy: An Immune-Related Adverse Event of PD-1 Inhibitor-A Report of 3 Cases.
Article in Kidney medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
- Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: A Report from the 34th Acute Disease Quality Initiative (ADQI) Consensus Conference.Journal of the American Society of Nephrology : JASN · 2026Article
- The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup.Nature reviews. Nephrology · 2026Review
- When our treatment is complicated: an overview of drug-induced acid-base disorders: part 1-acidosis.Pediatric nephrology (Berlin, Germany) · 2026Review
- Tislelizumab-induced distal renal tubular acidosis presenting with life-threatening hypokalemia: a case report.Frontiers in immunology · 2026Article
- Incidence of Immune Checkpoint Inhibitor-Associated Renal Tubular Acidosis.Kidney international reports · 2025Article
- The differentiation and intervention strategies for acute kidney injury after or induced by immune checkpoint inhibitors.American journal of cancer research · 2025Review
- Pembrolizumab-induced Acute Tubulointerstitial Nephritis Accompanying Fanconi Syndrome and Type 1 Renal Tubular Acidosis.Internal medicine (Tokyo, Japan) · 2024Article
- Refractory hypokalemia and metabolic acidosis induced by undifferentiated connective tissue disease secondary to immune checkpoint inhibitors: a case report and literature review.Frontiers in oncology · 2024Article
- Immune checkpoint inhibitors and acute kidney injury.Frontiers in immunology · 2024Review
- Nephrotoxicity in the Age of Immune Checkpoint Inhibitors: Mechanisms, Diagnosis, and Management.International journal of molecular sciences · 2023Review
- Immune checkpoint inhibitors and their interaction with proton pump inhibitors-related interstitial nephritis.Clinical kidney journal · 2023Review
- Anti‑PD1 therapy‑associated distal renal tubular acidosis: A case report.Experimental and therapeutic medicine · 2023Article
- Immunotherapy in oncology and the kidneys: a clinical review of the evaluation and management of kidney immune-related adverse events.Clinical kidney journal · 2023Review
- Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury.Nature reviews. Nephrology · 2022Review
- Zoledronic Acid-Associated Fanconi Syndrome in Patients With Cancer.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2022Article
- Immunotherapies and Renal Injury.Current opinion in toxicology · 2022Article
- Acute Kidney Injury Induced by Immune Checkpoint Inhibitors.Kidney diseases (Basel, Switzerland) · 2022Review
- Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge.Frontiers in nephrology · 2022Review
- A Rare Presentation of Checkpoint Inhibitor Induced Distal RTA.Case reports in oncological medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The main cause of acute kidney injury in patients receiving immune checkpoint inhibitors (ICIs) is acute interstitial nephritis. However, as their use continues to increase, other kidney manifestations are being described. We report 3 cases of patients treated with ICIs who developed predominantly electrolyte disorders secondary to renal tubular acidosis as an immune-related adverse event and discuss the potential mechanism. Nongap acidosis in combination with hypokalemia should raise suspicion for distal renal tubular acidosis in patients treated with ICIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.